Ischemic Stroke Model Development Services

Creative Biolabs provides custom ischemic stroke model development services for research on cerebral ischemia, reperfusion injury, neurovascular damage, neuroprotection, and functional recovery. We support model selection, pilot qualification, surgical induction, test article administration, physiological monitoring, behavioral assessment, tissue analysis, and study reporting. Programs can be configured around transient or permanent middle cerebral artery occlusion, localized photothrombosis, or embolic occlusion, according to the biological question and the evidence needed for the next development decision.

Study Design for the Intended Therapeutic Question

The study starts with the mechanism the candidate is expected to influence. A treatment intended to preserve tissue during an acute ischemic episode needs a different experimental window from a therapy intended to improve circuit function after an established infarct. We define when ischemia begins, whether and when reperfusion occurs, when treatment starts, and which outcome will carry the primary efficacy conclusion. These choices determine the model, sampling strategy, and duration of follow-up.

Acute Neuroprotection and Reperfusion Injury

Transient MCAO can be considered when the research question involves tissue injury during interrupted perfusion and the subsequent response to restored flow. Dosing can be aligned to occlusion onset, filament withdrawal, or a defined interval after reperfusion. Blood flow measurements help establish that the intended vascular event occurred. The protocol separates an effect on reperfusion from a direct effect on downstream tissue injury, and records temperature, anesthesia exposure, and recovery conditions that could influence the apparent treatment response.

Thrombolysis and Embolic Mechanisms

For a candidate expected to dissolve a clot, the obstructing material must be susceptible to the proposed mechanism. A clot-based embolic model can address recanalization, downstream perfusion, infarction, and hemorrhagic transformation. Filament withdrawal creates mechanical reperfusion and does not measure clot dissolution. Likewise, inert microspheres can model embolic obstruction but cannot establish fibrinolytic activity. Clot composition, stability, delivery, and the vascular monitoring plan are therefore central design variables for a thrombolytic program.

Recovery and Neurovascular Repair

Recovery studies can evaluate interventions that begin after the initial lesion has formed. Repeated functional measurements establish the trajectory of impairment and improvement, while terminal analyses examine tissue preservation, glial responses, vascular remodeling, or synaptic changes. The design distinguishes early protection from later restoration by defining the treatment start and, where feasible, obtaining an initial lesion assessment before treatment allocation. Rehabilitation exposure and task practice are standardized because both can influence performance independently of the candidate.

Focused surgical programs can be coordinated through Middle Cerebral Artery Occlusion Model Development Service or Photothrombosis Model Development Service.

Select a Model That Matches the Stroke Biology

CBL offers a robust portfolio of in vivo ischemic stroke models, each carefully chosen to address specific research questions and enhance translational relevance.

• Middle Cerebral Artery Occlusion Model Development
• Photothrombosis Model Development
• Four-Vessel Occlusion Model Development
• Two-Vessel Occlusion Model Development

Lesion Territory and Reperfusion Are Independent Choices

A proximal MCA occlusion may involve cortical and subcortical territories, whereas a distal occlusion or localized photothrombotic lesion can emphasize a more restricted cortical region. Final injury distribution depends on vascular anatomy, collateral supply, occlusion configuration, and monitoring conditions. Permanent occlusion does not automatically mean a larger infarct than every transient configuration. The selected anatomy must leave a measurable functional window, particularly when the study is intended to assess recovery rather than a terminal lesion measurement alone.

Species and Biological Context

Mouse and rat studies can be scoped according to genetic requirements, surgical feasibility, tissue demand, behavioral testing, and longitudinal imaging. Age, strain, sex, baseline performance, and relevant comorbid conditions are documented in the design. Aged or metabolically altered cohorts may change survival, lesion variability, drug exposure, and recovery, so they require their own feasibility assessment. A result in a healthy young cohort should not be presented as evidence that the same effect will occur across all stroke populations.

Global Ischemia as a Separate Research Route

When the primary question is diffuse cerebral hypoperfusion after circulatory arrest or systemic compromise, a global ischemia configuration may be more appropriate than a focal stroke model. Two-vessel or four-vessel approaches require species-specific interpretation and physiological control. We scope such studies separately because selective neuronal vulnerability and delayed injury differ from focal arterial infarction. This distinction keeps the model aligned with the intended indication and avoids treating all reductions in cerebral blood flow as equivalent.

Pilot Qualification Before Efficacy Testing

A pilot can qualify the intended injury window, confirm the monitoring approach, and determine whether the planned functional tasks detect a useful range of impairment. Prespecified criteria may address perfusion change, lesion location, postoperative status, technical complications, and endpoint quality. Thresholds are chosen for the actual species, monitoring position, and model configuration. The pilot also informs sample-size assumptions and attrition planning; it does not guarantee that the definitive study will reproduce a particular treatment effect.

Build a Coordinated Endpoint Package

Cerebral Blood Flow and Reperfusion

Laser Doppler flowmetry or laser speckle contrast imaging can be considered to document perfusion relative to baseline during occlusion and reperfusion. Probe placement or image regions, acquisition settings, motion control, and normalization are fixed in advance. Local cortical measurements may not represent all deep tissue territories. For embolic studies, additional vessel or perfusion assessments can help distinguish persistent occlusion, partial recanalization, and restored tissue perfusion. Physiological records accompany lesion outcomes so that a smaller lesion can be interpreted in the context of the vascular event.

Infarct Volume Edema and Tissue Injury

Terminal lesion assessment may use TTC staining in a suitable acute window or histological methods matched to later tissue changes. Longitudinal MRI can support repeated lesion measurements and assessment of edema or tissue evolution, subject to project feasibility. The analysis plan specifies section spacing, anatomical boundaries, image thresholds, hemisphere measurements, and the approach to edema correction. Raw and corrected values should be distinguished. At later time points, tissue loss and atrophy require an analysis strategy suited to chronic pathology rather than an acute swelling correction.

Neurological and Sensorimotor Recovery

Neurological scores provide an overall assessment, while adhesive removal, cylinder testing, grid walking, limb placement, rotarod, or gait analysis can address more specific deficits. We select tasks according to lesion location and expected severity, and establish baseline training and assessor consistency. Repeated measurements capture recovery over time. Apparent improvement must be interpreted alongside sedation, motivation, body mass, sensory capacity, and general health. Cognitive testing is added only when the model and residual motor function allow the result to be interpreted.

Blood Brain Barrier and Neurovascular Injury

Barrier-focused programs can combine tracer leakage or endogenous protein extravasation with vascular and tight-junction markers. Sampling regions distinguish the core, peri-infarct tissue, and an appropriate reference region. Hemorrhagic transformation is assessed separately from vascular permeability, especially in recanalization or combination-treatment studies. Endothelial injury, pericyte-associated changes, basement membrane integrity, microvascular density, and inflammatory-cell interactions can be included when they address the candidate mechanism. A single marker is interpreted within the broader vascular and tissue context.

Inflammation Cell Injury and Target Engagement

Histology and molecular analyses can examine neuronal survival, astroglial reactivity, microglial and macrophage responses, cytokines, oxidative stress, cell-death pathways, or candidate-specific signaling. Iba1 and related markers alone do not resolve every myeloid population or functional state. Cell identity and mechanism claims require appropriate additional evidence. Sampling time is equally important: an acute inflammatory signal, a later glial response, and a chronic remodeling endpoint represent different biological processes and should not be collapsed into one generic efficacy panel.

Endpoint timing is agreed for the selected configuration. Acute lesion measurement and chronic recovery commonly require different cohorts or a longitudinal imaging design because terminal tissue collection prevents subsequent behavioral follow-up.

Connect In Vivo Findings with Complementary Models

A complementary in vitro experiment can test a focused cellular hypothesis that is difficult to isolate in the whole animal. Ischemic Stroke Model based In Vitro Assay Service can support oxygen and glucose deprivation or related injury paradigms. This route can help explore treatment timing and cellular responses before a larger animal study, while recognizing that a culture system cannot reproduce arterial occlusion, systemic physiology, and whole-organ recovery.

For barrier or multicellular questions, consider iPSC derived BBB Model Generation Service, Cerebrovascular Disorder Organoid Modeling Service, or Neural Co-Culture Cellular Model Development Service. These systems can provide human cellular context and targeted follow-up of vascular or neural interactions. Cross-model comparisons use aligned exposure conditions and endpoints where possible; matching a marker change across systems does not by itself establish equivalent pharmacology or predict clinical efficacy.

Related Research

The following independent studies illustrate endpoint and timing decisions relevant to ischemic stroke model development. They provide published research context and do not represent Creative Biolabs project results.

Quantifying Different Infarct Patterns with MRI

Mulder and colleagues evaluated automated lesion segmentation in mouse MRI data after transient MCAO. Their figure compares segmentation across different lesion patterns and includes corresponding histology. The example supports a practical study-design point: anatomical diversity and edema can complicate lesion delineation, so image processing should be qualified against reference assessments. For an efficacy program, regions, thresholds, and review rules should be fixed before group identities are revealed. Agreement with a reference method in one data set does not guarantee equivalent performance with a different acquisition protocol or injury configuration.

Fig. 1 MRI and histological views of differing ischemic lesion patterns.^1,3

Following Secondary Injury Beyond the Acute Infarct

Li and colleagues studied thalamic changes after transient MCAO in rats using neurological assessment, contrast-enhanced MRI, and immunofluorescence. Their design included observations at one week, two weeks, and two months. Several glial and clearance-related abnormalities were most pronounced at the two-week assessment. The study illustrates why sampling should reflect the biological process under investigation: a single early infarct endpoint may miss later secondary pathology. Its specific intrathecal contrast procedure is a specialized research approach, and its feasibility and potential procedural effects require separate consideration before inclusion in a custom study.

Fig. 2 Assessment schedule for secondary pathology after transient MCAO in rats.^2,3

Frequently Asked Questions

1. Which ischemic stroke model should I choose?

   Model selection depends on the vascular mechanism, lesion territory, reperfusion conditions, treatment window, and endpoint. Transient MCAO supports controlled ischemia and reperfusion studies; permanent MCAO addresses sustained occlusion; photothrombosis supports targeted focal injury; clot-based embolic models are appropriate when clot lysis or recanalization is central.

2. Can a filament MCAO study demonstrate thrombolytic activity?

   Filament withdrawal provides mechanical reperfusion without dissolving a clot. It can support downstream protection or reperfusion-injury studies, but it cannot directly establish fibrinolytic activity. A thrombolysis study requires a suitable clot-based model with measurements of vascular patency, tissue perfusion, injury, and relevant bleeding outcomes.

3. How is a successful model confirmed?

   Confirmation can combine prespecified perfusion changes, documented occlusion and reperfusion timing, postoperative observations, and lesion or imaging criteria. Acceptance thresholds are qualified for the selected model and monitoring setup. Technical failures, exclusions, mortality, and missing data are retained in the study record and reported.

4. Can you evaluate long-term functional recovery?

   Recovery programs can include baseline training and repeated neurological or sensorimotor assessments over a project-specific follow-up period. Tasks are selected for lesion anatomy and severity. Longitudinal imaging and later tissue analysis can provide supporting information, and treatment timing is defined to distinguish early protection from later recovery effects.

5. Which imaging and tissue endpoints can be included?

   Depending on feasibility and study scope, options can include perfusion monitoring, MRI, TTC or histological lesion assessment, edema or tissue-loss analysis, neuronal and glial markers, blood brain barrier measures, hemorrhagic transformation, molecular biomarkers, and target engagement. Assays and sampling regions are selected for the mechanism and time point.

6. Can age sex or comorbidities be incorporated?

   These factors can be incorporated when compatible with the selected model and project scope. Because they may influence perfusion, mortality, lesion variability, drug exposure, and recovery, the study may require additional pilot qualification and revised sample-size assumptions. Cohort characteristics are defined before the definitive experiment.

7. Can in vitro stroke or BBB studies be added?

   Complementary oxygen and glucose deprivation assays, BBB models, organoids, or neural co-cultures can be scoped to investigate focused cellular mechanisms. The comparison should align exposure and endpoints where possible while recognizing that cellular systems do not reproduce arterial occlusion, systemic physiology, or whole-animal recovery.

8. What information is needed for a study proposal?

   Please provide the therapeutic hypothesis, test article and formulation, administration route, intended dosing window, preferred model or species, comparator groups, primary endpoint, follow-up period, imaging and tissue needs, available pilot data, and reporting requirements. These inputs allow feasibility, milestones, deliverables, and an estimated schedule to be scoped.

References

1. Mulder, Inge A., et al. "Automated Ischemic Lesion Segmentation in MRI Mouse Brain Data after Transient Middle Cerebral Artery Occlusion." Frontiers in Neuroinformatics, vol. 11, 2017, article 3. https://doi.org/10.3389/fninf.2017.00003
2. Li, Chanchan, et al. "Glymphatic System in the Thalamus, Secondary Degeneration Area Was Severely Impaired at 2nd Week after Transient Occlusion of the Middle Cerebral Artery in Rats." Frontiers in Neuroscience, vol. 16, 2022, article 997743. https://doi.org/10.3389/fnins.2022.997743
3. Distributed under Open Access license CC BY 4.0, without modification.